cfDNA-Based NGS IG Analysis in Lymphoma.
Cell-free DNA
Digital droplet PCR
Immunoglobulin rearrangements
Liquid biopsy
Minimal residual disease
Next-generation sequencing
Plasma
Therapy monitoring
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
1
6
2022
Statut:
ppublish
Résumé
Liquid biopsy is a novel diagnostic approach at first developed to characterize the molecular profile of solid tumors by analyzing body fluids. For cancer patients, it represents a noninvasive way to monitor the status of the solid tumor with respect to representative biomarkers. There is growing interest in the utilization of circulating tumor DNA (ctDNA) analysis also in the diagnostic and prognostic fields of lymphomas. Clonal immunoglobulin (IG) gene rearrangements are fingerprints of the respective lymphoid malignancy and thus are highly suited as specific molecular targets for minimal residual disease (MRD) detection. Tracing of the clonal IG rearrangement patterns in ctDNA pool during treatment can be used for MRD assessment in B-cell lymphomas. Here, we describe a reproducible next-generation sequencing assay to identify and characterize clonal IG gene rearrangements for MRD detection in cell-free DNA.
Identifiants
pubmed: 35622323
doi: 10.1007/978-1-0716-2115-8_7
pmc: PMC9761545
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
Circulating Tumor DNA
0
Immunoglobulins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-117Informations de copyright
© 2022. The Author(s).
Références
Anal Bioanal Chem. 2014 Oct;406(26):6499-512
pubmed: 24853859
Leukemia. 2019 Sep;33(9):2227-2240
pubmed: 31197258
Leukemia. 2003 Jun;17(6):1051-7
pubmed: 12764368
Genes Chromosomes Cancer. 2018 Mar;57(3):123-139
pubmed: 29205637
J Immunol. 2004 Sep 15;173(6):3878-88
pubmed: 15356136
J Neurooncol. 2016 May;128(1):93-100
pubmed: 26961773
Dis Markers. 2015;2015:574120
pubmed: 26412928
Leukemia. 2019 Sep;33(9):2254-2265
pubmed: 31227779
Cancer Res. 1977 Mar;37(3):646-50
pubmed: 837366
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Clin Chem. 2000 Jan;46(1):132-3
pubmed: 10620587
Clin Chem. 2015 Mar;61(3):514-22
pubmed: 25605683
Bioinformatics. 2017 Feb 1;33(3):435-437
pubmed: 28172348
Oncotarget. 2016 Jun 14;7(24):35818-35831
pubmed: 27127882